Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) price on Thursday, February 06, rose 0.46% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $17.29.
A look at the stock’s price movement, the close in the last trading session was $17.21, moving within a range at $17.24 and $17.58. The beta value (5-Year monthly) was 0.868. Turning to its 52-week performance, $22.80 and $11.83 were the 52-week high and 52-week low respectively. Overall, TEVA moved -17.94% over the past month.
Teva- Pharmaceutical Industries Ltd. ADR’s market cap currently stands at around $19.62 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 4B for the company’s revenue for the quarter, with a low and high estimate of 3.91B and 4.08B respectively. The average forecast suggests up to a 4.68% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 17.06B, representing a 3.14% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TEVA is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend TEVA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TEVA’s current price about -14.20% and -11.89% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 29.21, while 7-day volatility ratio is 2.79% and 3.24% in the 30-day chart. Further, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has a beta value of 0.82, and an average true range (ATR) of 0.76. Analysts have given the company’s stock an average 52-week price target of $25.5, forecast between a low of $22 and high of $28. Looking at the price targets, the low is -27.24% off current price level while to achieve the yearly target high, price needs to move -61.94%. Nonetheless, investors will most likely welcome a -47.48% jump to $25.5 which is the analysts’ median price.
If we refocus on Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA), historical trading data shows that trading volumes averaged 18.35 over the past 10 days and 11.42 million over the past 3 months. The company’s latest data on shares outstanding shows there are 1.13 billion shares.
The 0.00% of Teva- Pharmaceutical Industries Ltd. ADR’s shares are in the hands of company insiders while institutional holders own 57.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 15.8 million on 2025-01-15, giving us a short ratio of 1.26. The data shows that as of 2025-01-15 short interest in Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stood at 139.999995 of shares outstanding, with shares short falling to 23.22 million registered in 2024-12-13. Current price change has pushed the stock -21.55% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TEVA stock continues to rise going into the next quarter.
